Category: oncogene (journal)

Wake Forest cancer lab blames ‘honest mistakes’ for retractions

A prominent cancer research lab is up to three retractions and six corrections for “highly similar” images in papers published between 2018 and 2022. 

The lab is led by Kounosuke Watabe at Wake Forest University School of Medicine in Winston-Salem, North Carolina. Watabe holds one of three Wake Forest professorships all funded by a $2.8 million donation for cancer research in 2016. 

Each of the retractions and corrections came after sleuth Kevin Patrick raised concerns about the articles on PubPeer in May 2024. Patrick, who identified instances of images in Watabe lab papers being “more similar than expected,” told Retraction Watch he wasn’t confident whether the image duplication could be attributed to misconduct. “I am never sure which is worse, misconduct or a pattern of errors. Neither seem to inspire confidence in the published results,” he said. 

Watabe did not respond to multiple requests for comment.

Continue reading Wake Forest cancer lab blames ‘honest mistakes’ for retractions

Former cancer researcher who sued university for discrimination hits 35 retractions

A cancer researcher who was once the subject of a misconduct investigation at an Illinois university more than 10 years ago has made his debut on the Retraction Watch Leaderboard with 35 retractions. 

Last month Oncogene, a Springer Nature title, retracted 15 articles by Jasti Rao, formerly of the University of Illinois College of Medicine at Peoria. A 2014 university investigation into his lab’s publications found manipulation and rotation of images that “‘show a disturbing pattern’ indicative that Rao acted intentionally or recklessly,” we previously reported.  Rao sued the university for wrongful termination but lost. 

More than 100 of Rao’s papers have comments on PubPeer, most originating from a user called Lotus azoricus. We now know that pseudonym belongs to sleuth Elisabeth Bik.

Continue reading Former cancer researcher who sued university for discrimination hits 35 retractions

UC Davis research director loses three papers for image manipulation

Allen Gao

A lead researcher at UC Davis has lost three decades-old papers from the same journal for image duplication, and the journal says it is investigating more. 

Allen Gao, director of research for the Department of Urologic Surgery at the institution is first last and corresponding author on the papers, published in The Prostate. 

The journal retracted the articles – published in 2002, 2004 and 2009 – in  February. The papers have been cited 42, 71, and 27 times respectively, according to Clarivate’s Web of Science.

Continue reading UC Davis research director loses three papers for image manipulation

“My dog ate the data:” Eight excuses journal editors hear

As a journal editor, are you tired of hearing the same excuses from authors who are facing allegations of problematic data? If so, you’re not alone.

Recently, an editor of the journal Oncogene co-authored an editorial in the journal listing the types of excuses he often hears — and why none of them is valid. Writing the article with editor Justin Stebbing of Imperial College/Imperial Healthcare NHS Trust is David Sanders of Purdue University. Sanders himself has raised allegations of misconduct against a cancer researcher (and is currently being sued for defamation as a result).

Here are the problematic excuses they encounter:

Continue reading “My dog ate the data:” Eight excuses journal editors hear

A university asked for numerous retractions. Eight months later, three journals have done nothing.

Anil Jaiswal

When journals learn papers are problematic, how long does it take them to act?

We recently had a chance to find out as part of our continuing coverage of the case of Anil Jaiswal at the University of Maryland, who’s retracted 15 papers (including two new ones we recently identified), and has transitioned out of cancer research. Here’s what happened.

As part of a public records request related to the investigation, we received letters that the University of Maryland sent to 11 journals regarding 26 “compromised” papers co-authored by Jaiswal, four of which had been retracted by the time of the letter. The letters were dated between August and September 2016 (and one in February) — although, in some cases, the journals told us they received the letter later. Since that date, three journals have retracted nine papers and corrected another, waiting between four and six months to take action. One journal published an editorial note of concern within approximately two months after the university letter.

And six journals have not taken any public action.

Continue reading A university asked for numerous retractions. Eight months later, three journals have done nothing.

Huh? Cancer paper gets retracted because of its correction

Here’s a rather odd case: When readers raised issues about some of the images in a 2008 cancer paper, the authors issued a correction last year. But when readers asked additional questions about the corrected images, the authors decided to retract the paper entirely, along with its correction.

Both the original and corrected versions were questioned on PubPeer.

Here’s the retraction notice for the 2008 article “PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2,” published in Oncogene, which includes a link to the July 2016 correction: Continue reading Huh? Cancer paper gets retracted because of its correction

Cancer research pioneer Robert Weinberg corrected Oncogene paper

onc_cimageRobert Weinberg, a prominent cancer researcher at the Whitehead Institute, issued a correction to a paper in Oncogene in May, fixing two errors missed during proofing.

We found this one a little late, obviously. It also appears to be a relatively minor correction, not one that appears worthy of retraction. We’ve gotten feedback from readers asking why we cover corrections; we chose to flag this one because Weinberg has had such an impact on his field — he discovered the first tumor-causing gene in humans, as well as the first tumor-suppressor gene — and his papers are often highly cited. He also has issued five retractions in the past, most of which for papers whose first author was a member of his lab, who is not a co-author on the Oncogene paper.

Here’s the correction note for “Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells:”

Continue reading Cancer research pioneer Robert Weinberg corrected Oncogene paper

MD Anderson researcher Aggarwal up to six corrections

cover (2)A highly cited cancer researcher at MD Anderson has notched three major corrections, all associated with problems in figures. One note cites “human error” as the cause.

Bharat Aggarwal is the last author on all three papers. He is now up to six corrections, two unexplained withdrawals, and two Expressions of Concern. He’s also threatened to sue us in the past, and has told us that his institution has been looking into his work.

Only one note specifies that the correction does not affect the paper’s conclusions.

First up: “Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling,” published in the International Journal of Cancer and cited 168 times, according to Thomson Scientific’s Web of Knowledge. The issues span two figures, according to the erratum note:

Continue reading MD Anderson researcher Aggarwal up to six corrections

Oncogene to retract breast cancer paper following years-old misconduct investigation

Oncogene is retracting a 2010 paper on the molecular details of breast cancer cells as they undergo metastasis following an investigation that discovered the first author had committed misconduct.

The thing is, the investigation concluded in 2012, and the paper — “miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers” — isn’t being retracted until next week.

According to Lucinda Haines, senior publishing manager at Nature Publishing Group, the paper will be retracted June 29.

We heard from Iris Behrmann, Head of the Life Sciences Research Unit at the University of Luxembourg:

Continue reading Oncogene to retract breast cancer paper following years-old misconduct investigation

Fudged figures sink breast cancer paper

oncogeneA prestigious cancer journal has pulled an article over “concerns” regarding some of the figures, which PubPeer commenters had tagged as suspect.

A few weeks after the paper was published on June 9, comments on PubPeer began accumulating. Commenters called out both potentially manipulated and repeated images. The exact timeline is not clear, because Oncogene does not list a date on the retraction notice, but by August 29 the paper had been retracted.

Here’s the notice for “IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer,” by researchers at Shanghai Jiaotong University School of Medicine and Ruijin Hospital, both in Shanghai, China, and the University of Michigan: Continue reading Fudged figures sink breast cancer paper